期刊文献+

快速免疫荧光法检测血浆NT-proBNP的分析性能评价 被引量:5

Evaluation of performance of a rapid immunofluorescence method for assaying plasma NT-proBNP
原文传递
导出
摘要 目的 评价快速免疫荧光(RAMP)法检测血浆NT-proBNP的分析性能.方法 RAMP法测定264名健康体检者及78例心衰患者血浆NT-proBNP,参照CLSI方法 学评价方案,评价RAMP法的精密度、线性、稳定性及干扰因素等,并与瑞士罗氏公司Elecsys法检测方法 进行比对.结果 CV=20%时RAMP法功能灵敏度为48 ng/L,CV=10%时灵敏度为57 ng/L,线性范围18~8 000 ng/L.RAMP法NT-proBNP室温下稳定24 h,4℃稳定3 d,-20 ℃稳定20 d,反复冻融3次对检测结果 无影响.EDTA-K2和肝素抗凝血浆RAMP法测定结果 比对,YEDTA-K2=0.953 9X肝素+0.365 2,R2=0.982,P〈0.01,n=40.两种类型的抗凝标本在两种方法 间的测量结果 差异无统计学意义(P>0.05).轻度溶血(Hb=2 g/L)对RAMP法和Elecsys法测定结果 影响较小,偏差〈5%,中、重度溶血(Hb=3~4 g/L)对结果 影响大,偏差>15%.加入3种浓度三酰甘油时RMAP法测定值从390 ng/L降为82 ng/L,Elecsys法测定值从390 ng/L降为178 ng/L;当标本中胆红素含量为16~330 μmol/L,两种方法 测定值从7 777 ng/L降为7 741 ng/L,RAMP法抗乳糜和黄疸的干扰能力与Elecsys法相近.45份EDTA-K2抗凝血浆标本用2种方法 检测比对,Passing和Bablok回归方程显示:YRAMP=0.972 8XElecsys-0.035 2,R2=0.994,P>0.05,n=45.78份肝素抗凝血浆标本用2种方法 检测比对,Passing和Bablok回归方程显示:YRAMP=0.983 2XElecsys-0.037 6,R2=0.991,P>0.05,n=78.健康人血浆NT-proBNP水平随年龄递增,与性别相关,女性为105(60~120)ng/L,男性为59(44~91)ng/L,女性高于男性(Z=3.264,P〈0.01).结论 RAMP快速免疫荧光法重复性,稳定性较好、线性范围宽,检测结果 与罗氏电化学发光法一致性较好. Objective To analyze the performance of a rapid immunofluorescence assay for plasma NT-proBNP. Methods Human plasma NT-proBNP was measured by RAMP in 264 healthy cases and 78 patients with heart failure. The precision, stability, linearity and interference factors of RAMP were evaluated according to the protocold from America CLSI. Meanwhile, the results were compared with those obtained by Elecsys. Results Functional sensitivity of RAMP in 20% CV and 10% CV were 48 ng/L and 57 ng/L respectively. The linear range was 18-8 000 ng/L. NT-proBNP in plasma samples detected by RAMP were stable at room temperature for 24 hours, 4 ℃ for 3 days and - 20 ℃ for 20 days. No influences on results were observed throughout three freeze-thaw cycles. The results measured by RAMP were compared between EDTA-K2 anticoagulant plasma and heparin anticoagulant plasma, which showed that YEDTA-K2 =0. 953 9 Xheparin + 0. 365 2 ( R2 = 0. 982, P 〈 0. 01, n = 40 ). The results of EDTA-K2 and heparin anticoagulant plasma using RAMP and Elecsys showed no significant difference( P >0. 05). Slight hemolysis( Hb 2 g/L)had small effect on the results of PAMP and Elecsys assays and deviations of them were below 5%. However median and heavy hemolysis( Hb 3-4 g/L )obviously influenced the results with deviation were more than 15%. The values measured by RMAP fell from 390 ng/L to 82 ng/L, and those measured by Elecsys method fell from 390 ng/L to 178 ng/L when 3 different concentrations of triacylglycerol were added, the values measured by two methods fell from 7 777 ng/L to 7 741 ng/L when bilirubin ( 16-330 μmol/L) was added. The anti-interference ability of RAMP method was similar to Elecsys. Results detected with two methods in 45 EDTA-K2 anticoagulant plasma samples were analyzed with Passing and Bablok regression.The regression equation was YRAMP = 0. 972 8XElecsys - 0. 035 2 (R2 = 0. 994, P > 0. 05, n = 45 ). When heparin anticoagulant plasma samples increased to 78 samples, Passing and Bablok regression equation showed:YRAMP= 0. 983 2XElecsys - 0. 037 6 ( R2 = 0. 991, P > 0. 05, n = 78 ). NT-proBNP levels in healthy adults were elevated along with age and related to the gender. The median value of female[105(60-120) ng/L] was higher than that of male [59 ( 44-91 ) ng/L, Z = 3. 264, P 〈 0. 01] significantly. Conclusions RAMP method has good repeatability, outstanding stability, and broad linear range. The results detected by RAMP is consistent with results detected by Elecsys.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2010年第12期1208-1212,共5页 Chinese Journal of Laboratory Medicine
关键词 肽碎片 利钠肽 荧光免疫测定 肝素 评价研究 Peptide fragments Natriuretic peptide, brain Fluoroimmunoassay Heparin Evalution studies
  • 相关文献

参考文献10

  • 1Hunt PJ,Richards AM,Nicholls MG,et al.Immunoreactive amino-terminal pro-brainnatriuretic peptide (NT-PROBNP):a new marker of cardiac impairment.Clin Endocrinol (Oxf),1997,47:287-296.
  • 2Vogeser M,Jacob K.B-type natriuretic peptide (BNP)-validation of an immediate response assay.Clin Lab,2001,47:29-33.
  • 3Clerico A,Iervasi G,Mariani G.Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormonesin humans.Horm Metab Res,1999,31:487-498.
  • 4Bettencourt P,Azevedo A,Pimenta J,et al.N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.Circulation,2004,110:2168-2174.
  • 5Azzazy HM,Christenson RH.B-type natriuretic peptide:physiologic role and assay characteristics.Heart Fail Rev,2003,8:315-320.
  • 6Lee-Lewandrowski E,Januzzi JL,Green SM,et al.Multi-Center Validation of the Response Biomedical Corporation RAMP(R) NT-proBNP Assay With Comparison to the Roche Diagnostics GmbH Elecsys(R) proBNP Assay.Clin Chim Acta,2007,386:20-24.
  • 7Christenson RH,Apple FS,Cannon CP,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines:Biomarkersof Acute Coronary Syndrome and Heart Failure.26th Arnold O.Beckman Conference,2004.Washington DC:American Association for Clinical Chemistry,2004.
  • 8Munagala VK,Burnett JC Jr,Redfield MM.The natriuretic peptides in cardiovascular medicine.Curr Probl Cardiol,2004,29:707 -769.
  • 9潘柏申,蔡乃绳,李清,范维琥,李勇,郭玮,周琰,陶青.表面健康人群氨基末端B型利钠肽参考范围调查[J].中华检验医学杂志,2006,29(1):23-26. 被引量:66
  • 10史晓敏,宋以信,徐国宾,夏铁安.人血清N端脑钠肽水平参考值范围及其测定稳定性的初步调查[J].中国实验诊断学,2004,8(5):451-455. 被引量:18

二级参考文献37

  • 1Bozkurt B,Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation ,2003,107 : 1231-1233.
  • 2White HD,French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol,2003,42 : 1917-1920.
  • 3Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Euro Heart J,2001,22 : 1527-1560.
  • 4Hunt SA,Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation ,2005,112 :e154-e235.
  • 5de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet ,2003,362:316-322.
  • 6Yeo KTJ, Wu AHB, Apple FS, et al. Muhicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta,2003,338 : 107-115.
  • 7Vasan RS. Expanding indications for natriuretic peptides:impottance of better new (research) protocols. Am Heart J ,2004,148:743-746.
  • 8Panteghini M,Pagani F,Yeo KTJ,et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem,2004,50:327-332.
  • 9Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation ,2004,110 : 104-106.
  • 10Redfield MM, Rodeheffer R J, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol,2002 ,40 :976-982.

共引文献81

同被引文献43

  • 1Martinez-Rumayor A,Richards AM,Burnett JC,et al.Biology of the Natriuretic Peptides.Am J Cardiol,2008,101:3-8.
  • 2Apple FS,Wu AH,Jaffe AS,et al.National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines:Analytical Issues for Biomarkers of Heart Failure.Clin Biochem,2008,41:222-226.
  • 3中华医学会心血管病学分会.中华心血管病杂志编辑委员会,急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,:38-208,195.
  • 4Clinical and Laboratory Standards Institute.User demonstration of performance for precision and accuracy; Approved guidelinesecond edition(EP15-A2).Wayne:CLSI,2004.
  • 5Clinical and Laboratory Standards Institute. Protocols for Determination of Limits of Detection and Limits of Quantitation;Approved Guideline(EP17-A).Wayne:CLSI,2003.
  • 6Clinical and Laboratory Standards Institute. Evaluation of the Linearity of Quantitative Analytical Methods ; Approved Guideline (EP6-A).Wayne:CLSI,2004.
  • 7Clinical and Laboratory Standards Institute.Interference testing in clinical chemistry; Approved Guideline-second Edition (EP7-A2).Wayne:CLSI,2005.
  • 8Clinical and Laboratory Standards Institute. How to define and determine reference intervals in the clinical laboratory; Approved guideline-second edition(C28-A2).Wayne:CLSI,2000.
  • 9Gorissen C,Baumgarten R,de Groot M,et al.Analytical and clinical performance of three natriuretic peptide tests in the emergency room.Clin Chem Lab Med,2007,45:678-684.
  • 10Yeo KT,Apple FS,Wu AH,et al.Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay.Clin Chim Acta,2003,338:107-115.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部